Search

Read the inspiring story of two MSK employees, Jennifer Brosnan and Santosha Vardhana, and why they lead Cycle For Survival teams to raise money to support research into rare cancers.

… Monday, June 10, 2024 Even when they’re off the clock, the people of MSK devote themselves to raising money for cancer research through events like Cycle for Survival® , MSK’s biggest fundraising event of the year, focused on conquering rare cancers. These are just two of the people who epitomize the

New MSK research sheds new light on how the gut protects itself by sensing gut bacteria; finds a subtype of glioma-associated macrophages that appear to play a pivotal role in progression; and demonstrates that reduced surgery is an option for some thyroid cancer patients.

… Tuesday, January 20, 2026   New research from Memorial Sloan Kettering Cancer Center (MSK) sheds new light on how the gut protects itself by sensing gut bacteria; finds a subtype of glioma-associated macrophages that appear to play a pivotal role in progression; and demonstrates that reduced surgery

Researchers have developed a new generation of microscopic particles for molecular imaging, constituting one of the first promising nanoparticle platforms that may be readily adapted for tumor targeting and treatment in the clinic.

… Monday, December 22, 2008 Researchers have developed a new generation of microscopic particles for molecular imaging, constituting one of the first promising nanoparticle platforms that may be readily adapted for tumor targeting and treatment in the clinic. Highly sensitive and specific probes and molecular

Read about why Jae Park joined his colleagues at MSK and New York-Presbyterian to publicly show a united stance against hate.

… Thursday, April 1, 2021 MSK hematologic oncologist Jae Park Jae Park Female doctor wearing a mask and surrounded by her colleagues A large group of doctors and nurses congregating Four doctors wearing white coats and masks A large group of doctors and nurses congregating Over the past few weeks, Jae

Charles Sawyers, MD, Director of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center and a Howard Hughes Medical Institute investigator, has been named a "Dream Team" leader by Stand Up To Cancer and will co-lead a collaborative team that will receive $15 million to study targeted therapies to treat women's cancers.

… Wednesday, May 27, 2009 Charles Sawyers , MD, Director of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center (MSKCC) and a Howard Hughes Medical Institute investigator, has been named a “Dream Team” leader by Stand Up To Cancer and will co-lead a collaborative team

Despite the recent development of novel hormonal therapies - such as enzalutamide and abiraterone - directed at the androgen receptor in the management of castration-resistant prostate cancer, a proportion of men have disease that progresses on these drugs.

… Monday, June 5, 2017 Despite the recent development of novel hormonal therapies - such as enzalutamide and abiraterone - directed at the androgen receptor in the management of castration-resistant prostate cancer, a proportion of men have disease that progresses on these drugs. In this video Dr. Howard

In a dramatic shift since the publication of margin guidelines for breast cancer surgery, lumpectomy rates have substantially increased and more-aggressive surgical options have been used less often, according to research findings from a new study being presented at the 2017 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The study will also be published in a corresponding issue of JAMA Oncology.

… Monday, June 5, 2017 In a dramatic shift since the publication of margin guidelines for breast cancer surgery, lumpectomy rates have substantially increased and more-aggressive surgical options have been used less often, according to research findings from a new study being presented at the 2017 annual

Thousands of oncology experts from around the world will gather in Atlanta from March 29 – April 3 for the American Association for Cancer Research (AACR) Annual Meeting 2019. Memorial Sloan Kettering experts are involved in notable research presented at the meeting and are available to comment on topics including immunotherapy, precision medicine and targeted treatments, genomics, cancer interception and prevention, clinical trial design, cancer health disparities, and more. For more information and to set up interviews or access photos and video, contact [email protected] and [email protected].

… Thursday, March 28, 2019 Thousands of oncology experts from around the world will gather in Atlanta from March 29 – April 3 for the American Association for Cancer Research (AACR) Annual Meeting 2019. This year’s theme, “ Integrative   Cancer Science • Global Impact • Individualized Patient Care ,“ reinforces

A small interfering RNA implant targeting KRAS G12D/G12V mutations has shown a promising trend toward improved overall survival and objective response rate in patients with locally advanced pancreatic cancer with these mutations, according to results of a multisite, international phase 2 clinical trial led by Memorial Sloan Kettering Cancer Center.

… Thursday, January 29, 2026 A small interfering RNA (siRNA) implant targeting KRAS G12D/G12V mutations has shown a promising trend toward improved overall survival (OS) and objective response rate (ORR) in patients with locally advanced pancreatic cancer (LAPC) with these mutations, according to results

Memorial Sloan Kettering Cancer Center (MSKCC) today announced a major commitment from publisher, real estate developer, and MSKCC Board member Mortimer B. Zuckerman of $100 million from his charitable trust toward Memorial Sloan Kettering's new cancer research facility, including a 23-story laboratory structure that opens this month. Mr. Zuckerman's donation is the largest single commitment by an individual in Memorial Sloan Kettering's history.

… Wednesday, May 10, 2006 Memorial Sloan Kettering Cancer Center (MSKCC) today announced a major commitment from publisher, real estate developer, and MSKCC Board member Mortimer B. Zuckerman of $100 million from his charitable trust toward Memorial Sloan Kettering’s new cancer research facility, including